Item type |
itemtype_ver1(1) |
公開日 |
2021-11-22 |
タイトル |
|
|
タイトル |
A simple method to distinguish residual elotuzumab from monoclonal paraprotein in immunofixation assays for multiple myeloma patients |
|
言語 |
en |
著者 |
Chen, Shurui
Kiguchi, Toru
Nagata, Yasuyuki
Tamai, Yotaro
Ikeda, Takeshi
Kajiya, Ryoko
Ono, Takaaki
Sugiyama, Daisuke
Nishikawa, Hiroyoshi
Akatsuka, Yoshiki
|
アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
キーワード |
|
|
主題Scheme |
Other |
|
主題 |
Elotuzumab |
キーワード |
|
|
主題Scheme |
Other |
|
主題 |
Immunofixation electrophoresis |
キーワード |
|
|
主題Scheme |
Other |
|
主題 |
Monoclonal antibody |
キーワード |
|
|
主題Scheme |
Other |
|
主題 |
Multiple myeloma |
キーワード |
|
|
主題Scheme |
Other |
|
主題 |
Therapeutic |
内容記述 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Negative immunofixation electrophoresis (IFE) of serum and/or urine is a diagnostic marker for determining a complete response (CR) after immunotherapy for multiple myeloma (MM). However, residual therapeutic antibodies such as elotuzumab (IgG-κ), can compromise IFE evaluation when the affected immunoglobulins belong to the same IgG-κ subclass. We thus sought to develop a simple and rapid method to treat patient serum before IFE to distinguish the residual elotuzumab. Serum samples from patients receiving elotuzumab were treated with a predetermined amount of soluble signaling lymphocyte activation molecule F7 (SLAMF7) protein and then subjected to conventional IFE testing. We tested our method in samples from 12 patients. The IgG-κ band in IFE disappeared or shifted after elotuzumab treatment in four patients with no bone marrow minimal residual disease and normalized free light chain, whereas seven patients with any sign of residual MM showed a remaining IgG-κ band after treatment. One-hour incubation of samples with 6–9 molar excess soluble SLAMF7 before IFE was sufficient to distinguish residual elotuzumab in 11 of 12 samples. This simple method does not require special reagents, can be performed in most clinical laboratories, and enables differentiation between patients with a CR and those requiring further treatment. |
|
言語 |
en |
出版者 |
|
|
出版者 |
Springer |
|
言語 |
en |
言語 |
|
|
言語 |
eng |
資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
出版タイプ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
関連情報 |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1007/s12185-021-03088-9 |
収録物識別子 |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
0925-5710 |
書誌情報 |
en : International Journal of Hematology
巻 113,
号 4,
p. 473-479,
発行日 2021-04
|
ファイル公開日 |
|
|
日付 |
2022-04-01 |
|
日付タイプ |
Available |